Otlertuzumab

Otlertuzumab (TRU‐016) is a humanized monoclonal antibody designed for the treatment of cancer.[1]

Otlertuzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetCD37
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC4660H7136N1246O1452S30
Molar mass104809.42 g·mol−1

This drug was developed by Emergent BioSolutions and has been in clinical trails for lymphoma and Chronic Lymphocytic Leukemia (CLL)[2]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.